Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection

Next Previous
Trial Profile

An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Mycobacterial infections; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
  • Focus Therapeutic Use
  • Acronyms ENCORE
  • Sponsors Savara Pharmaceuticals

    • Most Recent Events

    • 13 Sep 2021 Number of treatment arms have been increased from 1 to 3 by the addition of two more groups, thus comprising 3 groups namely negative culture, positive culture and those not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen. Intervention model is changed from single-group assignment to parallel assignment.
    • 03 Sep 2020 Results presented in the Savara Pharmaceuticals Media Release.
    • 03 Sep 2020 According to an Savara Pharmaceuticals media release, the decision to discontinue the study was not based on safety concerns.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top